Key points are not available for this paper at this time.
5α-reductase inhibitors' potential benefits in preventing prostate cancer and potential increased risk for high-grade cancers have been central issues for the FDA, which convened its Oncologic Drugs Advisory Committee to address the topic last December.
Theoret et al. (Wed,) studied this question.